Trends and practices for managing low-risk prostate cancer: a SEER-Medicare study

[1]  M. Cooperberg,et al.  Regional Variation in Active Surveillance for Low-Risk Prostate Cancer in the US , 2020, JAMA network open.

[2]  A. D'Amico,et al.  Association Between African American Race and Clinical Outcomes in Men Treated for Low-Risk Prostate Cancer With Active Surveillance. , 2020, JAMA.

[3]  James D. Murphy,et al.  African-American men with low-risk prostate cancer treated with radical prostatectomy in an equal-access health care system: implications for active surveillance , 2020, Prostate Cancer and Prostatic Diseases.

[4]  M. Cooperberg,et al.  The New Surveillance, Epidemiology, and End Results Prostate with Watchful Waiting Database: Opportunities and Limitations. , 2020, European urology.

[5]  Jonathan E. Shoag,et al.  Active Surveillance for Black Men with Low-Risk Prostate Cancer in the United States. , 2019, The New England journal of medicine.

[6]  D. Penson,et al.  Selecting Active Surveillance: Decision Making Factors for Men with a Low-Risk Prostate Cancer , 2019, Medical decision making : an international journal of the Society for Medical Decision Making.

[7]  A. D'Amico,et al.  Active Surveillance for Low-Risk Prostate Cancer in Black Patients. , 2019, The New England journal of medicine.

[8]  A. D'Amico,et al.  Use of Active Surveillance or Watchful Waiting for Low-Risk Prostate Cancer and Management Trends Across Risk Groups in the United States, 2010-2015 , 2019, JAMA.

[9]  Ronald C. Chen,et al.  Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Part II: Recommended Approaches and Details of Specific Care Options , 2018, The Journal of urology.

[10]  J. Tward,et al.  Factors influencing prostate cancer patterns of care: An analysis of treatment variation using the SEER database , 2018, Advances in radiation oncology.

[11]  Ronald C. Chen,et al.  Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Part I: Risk Stratification, Shared Decision Making, and Care Options , 2017, The Journal of urology.

[12]  B. Hadaschik,et al.  The Value of PSA Density in Combination with PI‐RADS™ for the Accuracy of Prostate Cancer Prediction , 2017, The Journal of urology.

[13]  T. Choueiri,et al.  Racial disparities in prostate cancer outcome among prostate-specific antigen screening eligible populations in the United States , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  M. Menon,et al.  Variation in Locoregional Prostate Cancer Care and Treatment Trends at Commission on Cancer Designated Facilities: A National Cancer Data Base Analysis 2004 to 2013 , 2017, Clinical genitourinary cancer.

[15]  E. Schaeffer,et al.  Is active surveillance a suitable option for African American men with prostate cancer? A systemic literature review , 2017, Prostate Cancer and Prostatic Diseases.

[16]  David C. Miller,et al.  Variation in Guideline Concordant Active Surveillance Followup in Diverse Urology Practices , 2017, The Journal of urology.

[17]  David Gillatt,et al.  10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. , 2017, The New England journal of medicine.

[18]  H. Lepor,et al.  How Active is Active Surveillance? Intensity of Followup during Active Surveillance for Prostate Cancer in the United States. , 2016, The Journal of urology.

[19]  M. Menon,et al.  Contemporary Management of Prostate Cancer Patients Suitable for Active Surveillance: A North American Population-based Study. , 2016, European urology focus.

[20]  M. Roobol,et al.  Compliance Rates with the Prostate Cancer Research International Active Surveillance (PRIAS) Protocol and Disease Reclassification in Noncompliers. , 2015, European urology.

[21]  Simon P. Kim,et al.  Contemporary Nationwide Patterns of Active Surveillance Use for Prostate Cancer. , 2015, JAMA internal medicine.

[22]  M. Cooperberg,et al.  Trends in Management for Patients With Localized Prostate Cancer, 1990-2013. , 2015, JAMA.

[23]  M. Litwin,et al.  Expectant management for men with early stage prostate cancer , 2015, CA: a cancer journal for clinicians.

[24]  L. Holmberg,et al.  Systematic Review and Meta-analysis of Factors Determining Change to Radical Treatment in Active Surveillance for Localized Prostate Cancer. , 2015, European urology.

[25]  Sam S. Chang,et al.  Increasing use of observation among men at low risk for prostate cancer mortality. , 2015, The Journal of urology.

[26]  Danny Vesprini,et al.  Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  India U.S. Consulate Chennai.  U.S. Department of Health & Human Services , 2014 .

[28]  M. Roobol,et al.  Active surveillance for low-risk prostate cancer worldwide: the PRIAS study. , 2013, European urology.

[29]  Alan W Partin,et al.  Active Surveillance Program for Prostate Cancer: An Update of the Johns Hopkins Experience , 2011 .

[30]  J. Mohler.  The 2010 NCCN clinical practice guidelines in oncology on prostate cancer. , 2010, Journal of the National Comprehensive Cancer Network : JNCCN.

[31]  Angela Mariotto,et al.  Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. , 2009, Journal of the National Cancer Institute.

[32]  A. D'Amico,et al.  Guideline for the management of clinically localized prostate cancer: 2007 update. , 2007, The Journal of urology.

[33]  J L Warren,et al.  Development of a comorbidity index using physician claims data. , 2000, Journal of clinical epidemiology.

[34]  R. Deyo,et al.  Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. , 1992, Journal of clinical epidemiology.

[35]  S. Lipsitz,et al.  Variation in the use of active surveillance for low‐risk prostate cancer , 2018, Cancer.

[36]  Sanjay G. Patel,et al.  National trends in the management of low and intermediate risk prostate cancer in the United States. , 2015, The Journal of urology.

[37]  B. Trock,et al.  Reclassification rates are higher among African American men than Caucasians on active surveillance. , 2015, Urology.

[38]  David C. Miller,et al.  Contemporary use of initial active surveillance among men in Michigan with low-risk prostate cancer. , 2015, European urology.

[39]  Steven J. M. Jones,et al.  A multi-institutional evaluation of active surveillance for low risk prostate cancer. , 2013, The Journal of urology.

[40]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.